Search research articles
Contact Us
Filters
Showing results (31-40 of 42) with videos related to
Page
of 5
Sort By:
Blood
|
March 29, 2003
Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen)
Alessandro M Gianni, Michele Magni, Maurizio Martelli, et al.
Cancer Research
|
February 3, 2006
The anti-human leukocyte antigen-DR monoclonal antibody 1D09C3 activates the mitochondrial cell death pathway and exerts a potent antitumor activity in lymphoma-bearing nonobese diabetic/severe combined immunodeficient mice
Carmelo Carlo-Stella, Massimo Di Nicola, Maria Caterina Turco, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
December 13, 2006
Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma
Marco Ladetto, Michele Magni, Gloria Pagliano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 26, 2004
Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced, CD34(+)-derived dendritic cell vaccination: a phase I trial in metastatic melanoma
Massimo Di Nicola, Carmelo Carlo-Stella, Roberta Mortarini, et al.
Scientific Reports
|
February 9, 2024
Immunological characterization of a long-lasting response in a patient with metastatic triple-negative breast cancer treated with PD-1 and LAG-3 blockade
Licia Rivoltini, Chiara Camisaschi, Giovanni Fucà, et al.
International Journal of Radiation Oncology, Biology, Physics
|
March 15, 2016
Addition of Rituximab to Involved-Field Radiation Therapy Prolongs Progression-free Survival in Stage I-II Follicular Lymphoma: Results of a Multicenter Study
Marco Ruella, Andrea Riccardo Filippi, Riccardo Bruna, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 21, 2008
Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innnovative nei linfomi survey
Corrado Tarella, Manuela Zanni, Michele Magni, et al.
Journal for Immunotherapy of Cancer
|
June 15, 2021
Fifteen-year follow-up of relapsed indolent non-Hodgkin lymphoma patients vaccinated with tumor-loaded dendritic cells
Giovanni Fucà, Margherita Ambrosini, Luca Agnelli, et al.
Clinical Genitourinary Cancer
|
December 24, 2013
Predictors of CD34+ cell mobilization and collection in adult men with germ cell tumors: implications for the salvage treatment strategy
Andrea Necchi, Rosalba Miceli, Paolo Pedrazzoli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 30, 2010
Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphoma
Corrado Tarella, Roberto Passera, Michele Magni, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 42) with videos related to
Sort By:
Page
of 5
Blood
|
March 29, 2003
Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen)
Alessandro M Gianni, Michele Magni, Maurizio Martelli, et al.
Cancer Research
|
February 3, 2006
The anti-human leukocyte antigen-DR monoclonal antibody 1D09C3 activates the mitochondrial cell death pathway and exerts a potent antitumor activity in lymphoma-bearing nonobese diabetic/severe combined immunodeficient mice
Carmelo Carlo-Stella, Massimo Di Nicola, Maria Caterina Turco, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
December 13, 2006
Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma
Marco Ladetto, Michele Magni, Gloria Pagliano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 26, 2004
Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced, CD34(+)-derived dendritic cell vaccination: a phase I trial in metastatic melanoma
Massimo Di Nicola, Carmelo Carlo-Stella, Roberta Mortarini, et al.
Scientific Reports
|
February 9, 2024
Immunological characterization of a long-lasting response in a patient with metastatic triple-negative breast cancer treated with PD-1 and LAG-3 blockade
Licia Rivoltini, Chiara Camisaschi, Giovanni Fucà, et al.
International Journal of Radiation Oncology, Biology, Physics
|
March 15, 2016
Addition of Rituximab to Involved-Field Radiation Therapy Prolongs Progression-free Survival in Stage I-II Follicular Lymphoma: Results of a Multicenter Study
Marco Ruella, Andrea Riccardo Filippi, Riccardo Bruna, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 21, 2008
Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innnovative nei linfomi survey
Corrado Tarella, Manuela Zanni, Michele Magni, et al.
Journal for Immunotherapy of Cancer
|
June 15, 2021
Fifteen-year follow-up of relapsed indolent non-Hodgkin lymphoma patients vaccinated with tumor-loaded dendritic cells
Giovanni Fucà, Margherita Ambrosini, Luca Agnelli, et al.
Clinical Genitourinary Cancer
|
December 24, 2013
Predictors of CD34+ cell mobilization and collection in adult men with germ cell tumors: implications for the salvage treatment strategy
Andrea Necchi, Rosalba Miceli, Paolo Pedrazzoli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 30, 2010
Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphoma
Corrado Tarella, Roberto Passera, Michele Magni, et al.
Page
of 5